Life Sciences · medium ·
Life sciences' AI build-out outruns its proprietary algorithm shortage
Major pharmaceutical companies are prioritising in-house ownership and development of AI capabilities over exclusive reliance on external partnerships. This involves strategic acquisitions and significant direct investments in AI infrastructure, driven by a desire to control proprietary algorithms and integrate AI deeply into core functions, thereby gaining competitive advantage.
Part of the Healthcare & Life Sciences Opportunity Outlook, Korim's monthly analysis of emerging opportunities in this sector.